Taysha gene therapies to participate in upcoming april investor healthcare conferences

Dallas--(business wire)--taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced its participation in virtual fireside chats for the 20th annual needham virtual healthcare conference and the chardan 5th annual manufacturing summit. conferences details:
TSHA Ratings Summary
TSHA Quant Ranking